Overview

• Triplet regimen combining gedatolisib with fulvestrant and palbociclib reduced risk of disease progression or death by 76% versus fulvestrant alone.
• Doublet regimen of gedatolisib and fulvestrant cut progression risk by 67% compared to fulvestrant monotherapy.
• The Phase 3 VIKTORIA-1 trial enrolled HR-positive, HER2-negative, PIK3CA wild-type patients after CDK4/6 inhibitor and aromatase inhibitor therapy.
• Celcuity’s stock surged more than 200% following the release of the topline PFS data.
• Full trial results will be presented at an upcoming medical conference and mutant-cohort outcomes are expected by year-end.